Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Cypher Genomics Ink Co-marketing Agreement

NEW YORK (GenomeWeb) – Cypher Genomics has signed a co-promotion agreement with Illumina that lets the sequencing vendor offer Cypher's Coral biomarker discovery service to pharmaceutical companies.

Specifically, under the terms of the agreement, Illumina's sales force will market Coral as part of a solution to pharma that includes sequencing and its NextBio platform for data analytics and storage. Pharma firms could, for example, use the service to analyze small groups of patients in early clinical trials to discover genetic markers that are linked to therapeutic response.

In a statement, Nick Naclerio, Illumina's senior vice president for corporate development and general manager for enterprise informatics, described Cypher's biomarker discovery service is "a perfect complement" to Illumina's offerings.

The combined offering will enable pharma companies to accelerate "their personalized drug development efforts and … ultimately help deliver on the promise of precision medicine," Adam Simpson, Cypher's president and chief operating officer, added.

Financial and other terms of the agreement were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.